Clinical Trial Update: Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy. [Phase 2]

View source ↗

Summary

A Phase Ib/II trial evaluates QL1706 plus Fruquintinib with SCRT versus standard third-line therapy in unresectable liver-metastatic pMMR/MSS colorectal cancer,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• QL1706

Snippet

Sponsor: Tao Zhang | Conditions: Colorectal Cancer | Phase 2 | Status: NOT_YET_RECRUITING